-
INHALE-1: A 26-week Primary Treatment Phase with 26-week Extension Open-label Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza Versus Rapid-acting Insulin Analog Injections Both in Combination with a Basal Insulin in Pediatric
The purpose of this study is to find out whether an inhaled, ultra-rapid-acting insulin (Afrezza) works as well as rapid-acting injections. The possible benefits of ...Phase
Interventional
Accepts Healthy Volunteer
